AVBP (ArriVent BioPharma) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Days Payable?

ArriVent BioPharma's average Accounts Payable for the three months ended in Sep. 2024 was $4.17 Mil. ArriVent BioPharma's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for ArriVent BioPharma's Days Payable or its related term are showing as below:

AVBP's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.37
* Ranked among companies with meaningful Days Payable only.

ArriVent BioPharma's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

ArriVent BioPharma Days Payable Historical Data

The historical data trend for ArriVent BioPharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Days Payable Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

ArriVent BioPharma Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of ArriVent BioPharma's Days Payable

For the Biotechnology subindustry, ArriVent BioPharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ArriVent BioPharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Days Payable distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Days Payable falls into.

ArriVent BioPharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

ArriVent BioPharma's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (3.094	+	4.532)	/	2 )	/	0	*	365
=	3.813					/	0	*	365
=	N/A

ArriVent BioPharma's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (3.812	+	4.532)	/	2 )	/	0	*	365 / 4
=	4.172					/	0	*	365 / 4
=	N/A

ArriVent BioPharma Days Payable Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073

Website

https://arrivent.com

ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.